- Home
- PBBK vs LITS Comparison
PBBK vs LITS Comparison
Compare PBBK & LITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PBBK | LITS |
|---|---|---|
| Founded | 1919 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.5M | 55.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PBBK | LITS |
|---|---|---|
| Price | $19.81 | $1.49 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 10.8K | ★ 799.7K |
| Earning Date | 02-25-2026 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 53.39 | N/A |
| EPS | ★ 0.98 | N/A |
| Revenue | ★ $13,918,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $20.21 | ★ N/A |
| Revenue Growth | ★ 17.20 | N/A |
| 52 Week Low | $14.23 | $1.30 |
| 52 Week High | $22.92 | $9.00 |
Technical Indicators
Market Signals| Indicator | PBBK | LITS |
|---|---|---|
| Relative Strength Index (RSI) | 43.68 | N/A |
| Support Level | $21.04 | N/A |
| Resistance Level | $21.95 | N/A |
| Average True Range (ATR) | 0.54 | 0.00 |
| MACD | -0.21 | 0.00 |
| Stochastic Oscillator | 9.43 | 0.00 |
Price Performance
Historical ComparisonAbout PBBK PB Bankshares Inc.
PB Bankshares Inc follows a community bank model and provides multiple services to individuals and small to midsize businesses. Its business consists of attracting retail and commercial deposits from the general public in its market area and investing those deposits, together with funds generated from operations and borrowings, in commercial real estate loans, commercial and industrial loans, construction, home equity lines of credit and to a lesser extent, one- to four-family residential real estate loans and consumer loans.
About LITS Lite Strategy Inc.
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.